Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 4/2012

01-10-2012 | Reproductive Medicine

A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest® when used for luteal phase support in ICSI treatment

Authors: Malek-Mansour Aghsa, Haleh Rahmanpour, Maryam Bagheri, Fatemeh Davari-Tanha, Reza Nasr

Published in: Archives of Gynecology and Obstetrics | Issue 4/2012

Login to get access

Abstract

Purpose

This study compares the efficacy, side effects and patient convenience of vaginal and rectal routes of administration of progesterone suppositories (Cyclogest) when used for luteal phase support during in vitro fertilization cycles, through the use of antagonist protocols.

Methods

147 patients who underwent intra-cytoplasmic sperm injection cycle were randomized on the day of the embryo transfer (ET) by a computer-generated randomization program to receive 400 mg of Cyclogest either vaginally or rectally twice daily for up to 8 weeks. A pregnancy test was conducted 2 weeks after embryo transfer. If the pregnancy test was negative, the application was discontinued. On day 14th after embryo transfer, patient’s acceptability and side effects were assessed using a questionnaire which was given to the patients on the day of ET prior to performing the pregnancy test. The clinical pregnancy rate at the 8th week of gestation and the level of luteal progesterone were evaluated.

Results

There were no substantial differences in the demographics or other characteristics between the two groups. There were no significant differences in serum P concentration 6 days after ET, the clinical pregnancy and abortion rates. The difficulty of administration route, the discomforts experienced following administration, and the proportion leaking out on the 14th day were similar between the two groups. Significantly more patients administering the medication per vagina had perineal irritation (21.3 vs. 2.2 %). The prevalence of tenesmus (35.1 vs. 21.1 %) and rectal itching (26.7 vs. 2.8 %) were significantly more in rectal route.

Conclusions

This study demonstrates that the efficacy of Cyclogest is similar when administered via both the vaginal and rectal routes. Although their side effects differ, the ease of administration for patients and their preference are similar.
Literature
1.
go back to reference Hubayter ZR, Muasher SJ (2008) Luteal supplementation in vitro fertilization: more questions than answers. Fertil Steril 89:749–758PubMedCrossRef Hubayter ZR, Muasher SJ (2008) Luteal supplementation in vitro fertilization: more questions than answers. Fertil Steril 89:749–758PubMedCrossRef
2.
go back to reference Dal Prato L, Borini A (2005) Use of antagonists in ovarian stimulation protocols. Reprod Biomed Online 10:330–338PubMedCrossRef Dal Prato L, Borini A (2005) Use of antagonists in ovarian stimulation protocols. Reprod Biomed Online 10:330–338PubMedCrossRef
3.
go back to reference Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P (2007) Update of luteal phase support in stimulated ICSI cycles. Hum Reprod Update 13:581–590PubMedCrossRef Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P (2007) Update of luteal phase support in stimulated ICSI cycles. Hum Reprod Update 13:581–590PubMedCrossRef
4.
go back to reference Fatemi HM (2009) The luteal phase after 3 decades of IVF: what do we know? Reprod Biomed Online 19:4331PubMedCrossRef Fatemi HM (2009) The luteal phase after 3 decades of IVF: what do we know? Reprod Biomed Online 19:4331PubMedCrossRef
5.
go back to reference Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM (2012) The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 24:134–141PubMedCrossRef Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM (2012) The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 24:134–141PubMedCrossRef
6.
go back to reference Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, Van Steirteghem A, Devroey P (1998) The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 70:357–359PubMedCrossRef Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, Van Steirteghem A, Devroey P (1998) The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 70:357–359PubMedCrossRef
7.
go back to reference Kolibianakis EM, Devroey P (2002) The luteal phase after ovarian stimulation. Reprod Biomed Online 5 Suppl 1 (3):26–35 Kolibianakis EM, Devroey P (2002) The luteal phase after ovarian stimulation. Reprod Biomed Online 5 Suppl 1 (3):26–35
8.
go back to reference Fauser BC, Devroey P (2003) Reproductive biology and ICSI: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 14:236–242PubMedCrossRef Fauser BC, Devroey P (2003) Reproductive biology and ICSI: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 14:236–242PubMedCrossRef
9.
go back to reference Bahceci M, Ulug U (2008) Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyper-stimulation for ICSI with ICSI using GnRH antagonist. J Assist Reprod Genet 25:499–502PubMedCrossRef Bahceci M, Ulug U (2008) Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyper-stimulation for ICSI with ICSI using GnRH antagonist. J Assist Reprod Genet 25:499–502PubMedCrossRef
10.
go back to reference ASRM Practice Committee (2008) Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. ASRM Practice Committee Position Statement. Fertil Steril 90:S150–S153 ASRM Practice Committee (2008) Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. ASRM Practice Committee Position Statement. Fertil Steril 90:S150–S153
11.
go back to reference Ng EHY, Chan CC, Tang OS, Ho PC (2007) A randomized comparison of side effects and patient convenience between Cyclogest1 suppositories and Endometrin1 tablets used for luteal phase support in ICSI treatment. Eur J Obstet Gynecol Reprod Biol 131:182–188PubMedCrossRef Ng EHY, Chan CC, Tang OS, Ho PC (2007) A randomized comparison of side effects and patient convenience between Cyclogest1 suppositories and Endometrin1 tablets used for luteal phase support in ICSI treatment. Eur J Obstet Gynecol Reprod Biol 131:182–188PubMedCrossRef
12.
go back to reference Daya S, Gunby J (2004) Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev CD004830 Daya S, Gunby J (2004) Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev CD004830
13.
go back to reference Nosarka S, Kruger T, Siebert I, Grove D (2005) Luteal phase support in in vitro fertilization: meta-analysis of randomized trials. Gynecol Obstet Invest 60:67–74PubMedCrossRef Nosarka S, Kruger T, Siebert I, Grove D (2005) Luteal phase support in in vitro fertilization: meta-analysis of randomized trials. Gynecol Obstet Invest 60:67–74PubMedCrossRef
14.
go back to reference Soliman S, Daya S, Collins J, Hughes EG (1994) The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil Steril 61:1068–1076PubMed Soliman S, Daya S, Collins J, Hughes EG (1994) The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil Steril 61:1068–1076PubMed
15.
go back to reference Araujo E, Bernadini L, Frederick JL, Asch RH, Balmaceda JP (1994) Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal phase support in assisted reproduction. J Assist Reprod Genet 11:74–78PubMedCrossRef Araujo E, Bernadini L, Frederick JL, Asch RH, Balmaceda JP (1994) Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal phase support in assisted reproduction. J Assist Reprod Genet 11:74–78PubMedCrossRef
16.
go back to reference Levine H, Watson N (2000) Comparison of the pharmacokinetics of crinone 8 % administered vaginally versus Prometrium administered orally in postmenopausal women (3). Fertil Steril 73:516–521PubMedCrossRef Levine H, Watson N (2000) Comparison of the pharmacokinetics of crinone 8 % administered vaginally versus Prometrium administered orally in postmenopausal women (3). Fertil Steril 73:516–521PubMedCrossRef
17.
go back to reference Tavaniotou A, Smitz J, Bourgain C, Devroey P (2000) Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update 6:139–148PubMedCrossRef Tavaniotou A, Smitz J, Bourgain C, Devroey P (2000) Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update 6:139–148PubMedCrossRef
18.
go back to reference Penzias AS, Alper MM (2003) Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed Online 6:287–295PubMedCrossRef Penzias AS, Alper MM (2003) Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed Online 6:287–295PubMedCrossRef
19.
go back to reference Schoolcraft WB, Hesla JS, Gee MJ (2000) Experience with progesterone gel for luteal support in a highly successful ICSI programme. Hum Reprod 15:1284–1288PubMedCrossRef Schoolcraft WB, Hesla JS, Gee MJ (2000) Experience with progesterone gel for luteal support in a highly successful ICSI programme. Hum Reprod 15:1284–1288PubMedCrossRef
20.
go back to reference Chakmakjian ZH, Zachariah NY (1987) Bioavailability of progesterone with different modes of administration. J Reprod Med 32:443–448PubMed Chakmakjian ZH, Zachariah NY (1987) Bioavailability of progesterone with different modes of administration. J Reprod Med 32:443–448PubMed
21.
go back to reference Ioannidis G, Sacks G, Reddy N, Seyani L, Margara R, Lavery S, Trew G (2005) Day 14 maternal serum progesterone levels predict pregnancy outcome in ICSI/ICSI treatment cycles: a prospective study. Hum Reprod 20:741–746PubMedCrossRef Ioannidis G, Sacks G, Reddy N, Seyani L, Margara R, Lavery S, Trew G (2005) Day 14 maternal serum progesterone levels predict pregnancy outcome in ICSI/ICSI treatment cycles: a prospective study. Hum Reprod 20:741–746PubMedCrossRef
22.
go back to reference Posaci C, Smitz J, Camus M, Osmanagaoglu K, Devroey P (2000) Progesterone for the luteal support of assisted reproductive technologies: clinical options. Hum Reprod 15(Suppl 1):129–148PubMedCrossRef Posaci C, Smitz J, Camus M, Osmanagaoglu K, Devroey P (2000) Progesterone for the luteal support of assisted reproductive technologies: clinical options. Hum Reprod 15(Suppl 1):129–148PubMedCrossRef
23.
go back to reference Moyer DL, de Lignieres B, Driguez P, Pez JP (1993) Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 59:992–997PubMed Moyer DL, de Lignieres B, Driguez P, Pez JP (1993) Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 59:992–997PubMed
24.
go back to reference Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B (2011) Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril 95:1961–1965PubMedCrossRef Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B (2011) Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril 95:1961–1965PubMedCrossRef
25.
go back to reference Kimzey LM, Gumowski J, Merriam GR, Grimes GJ Jr, Nelson LM (1991) Absorption of micronized progesterone from a non-liquefying vaginal cream. Fertil Steril 56:995–996PubMed Kimzey LM, Gumowski J, Merriam GR, Grimes GJ Jr, Nelson LM (1991) Absorption of micronized progesterone from a non-liquefying vaginal cream. Fertil Steril 56:995–996PubMed
26.
go back to reference Archer D, Fahy G, Viniegra-Sibal A, Anderson FD, Snipes W, Foldesy RG (1995) Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. Am J Obstet Gynecol 173:471–478PubMedCrossRef Archer D, Fahy G, Viniegra-Sibal A, Anderson FD, Snipes W, Foldesy RG (1995) Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. Am J Obstet Gynecol 173:471–478PubMedCrossRef
27.
go back to reference Pouly JL, Bassil S, Frydman R et al (1996) Luteal support after in vitro fertilization: crinone 8 %, a sustained release vaginal progesterone gel, vs. utrogestan, an oral micronized progesterone. Hum Reprod 11:2085–2089PubMedCrossRef Pouly JL, Bassil S, Frydman R et al (1996) Luteal support after in vitro fertilization: crinone 8 %, a sustained release vaginal progesterone gel, vs. utrogestan, an oral micronized progesterone. Hum Reprod 11:2085–2089PubMedCrossRef
28.
go back to reference Ng EHY, Miao B, Cheung W, Ho PC (2003) A randomized comparison of side effects and patient convenience of two vaginal progesterone formulations used for luteal support in in vitro fertilization cycles. Eur J Obstet Gynecol Reprod Biol 111:50–54PubMedCrossRef Ng EHY, Miao B, Cheung W, Ho PC (2003) A randomized comparison of side effects and patient convenience of two vaginal progesterone formulations used for luteal support in in vitro fertilization cycles. Eur J Obstet Gynecol Reprod Biol 111:50–54PubMedCrossRef
Metadata
Title
A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest® when used for luteal phase support in ICSI treatment
Authors
Malek-Mansour Aghsa
Haleh Rahmanpour
Maryam Bagheri
Fatemeh Davari-Tanha
Reza Nasr
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 4/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-012-2410-7

Other articles of this Issue 4/2012

Archives of Gynecology and Obstetrics 4/2012 Go to the issue